{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:37:31Z","timestamp":1793288251779,"version":"4.5.0"},"reference-count":122,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal de Mycologie M\u00e9dicale"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.mycmed.2020.101007","type":"journal-article","created":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T13:49:46Z","timestamp":1592660986000},"page":"101007","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":102,"title":["Mucormycosis treatment: Recommendations, latest advances, and perspectives"],"prefix":"10.1016","volume":"30","author":[{"given":"K.","family":"Brunet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Rammaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mycmed.2020.101007_bib0005","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.idc.2015.10.011","article-title":"Mucormycoses","volume":"30","author":"Farmakiotis","year":"2016","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.mycmed.2020.101007_bib0010","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/jof5010023","article-title":"Disease entities in Mucormycosis","volume":"5","author":"Serris","year":"2019","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.mycmed.2020.101007_bib0015","article-title":"Therapy of Mucormycosis","volume":"4","author":"Sipsas","year":"2018","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.mycmed.2020.101007_bib0020","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1469-0691.2009.02984.x","article-title":"In vitro activity of antifungals against Zygomycetes","volume":"15","author":"Alastruey-Izquierdo","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.mycmed.2020.101007_bib0025","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1128\/AAC.01512-07","article-title":"In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species","volume":"52","author":"Guinea","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0030","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/j.1469-0691.2008.02086.x","article-title":"EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds","volume":"14","author":"Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.mycmed.2020.101007_bib0035","series-title":"Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. M38-A2","author":"CLSI","year":"2008"},{"key":"10.1016\/j.mycmed.2020.101007_bib0040","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/jof5010026","article-title":"Global epidemiology of Mucormycosis","volume":"5","author":"Prakash","year":"2019","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.mycmed.2020.101007_bib0045","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.mycmed.2020.101007_bib0050","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.mycmed.2020.101007_bib0055","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1093\/jac\/dkv236","article-title":"Prospective pilot study of high-dose (10mg\/kg\/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis","volume":"70","author":"Lanternier","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0060","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/jac\/dkr375","article-title":"The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial","volume":"67","author":"Spellberg","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0065","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/590004","article-title":"Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis","volume":"47","author":"Chamilos","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mycmed.2020.101007_bib0070","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1182\/blood-2011-03-316430","article-title":"How I treat mucormycosis","volume":"118","author":"Kontoyiannis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.mycmed.2020.101007_bib0075","first-page":"79","article-title":"Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections","volume":"9","author":"Donnelley","year":"2016","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.mycmed.2020.101007_bib0080","doi-asserted-by":"crossref","first-page":"7735","DOI":"10.1128\/AAC.01919-15","article-title":"In vitro activity of isavuconazole and comparators against clinical isolates of the mucorales order","volume":"59","author":"Arendrup","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0085","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1128\/AAC.02301-13","article-title":"Isavuconazole therapy protects immunosuppressed mice from Mucormycosis","volume":"58","author":"Luo","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0090","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.mycmed.2020.101007_bib0095","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1093\/cid\/ciy406","article-title":"Breakthrough fungal infections in patients with leukemia receiving isavuconazole","volume":"67","author":"Rausch","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mycmed.2020.101007_bib0100","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01896-18","article-title":"Preexposure to isavuconazole increases the virulence of mucorales but not Aspergillus fumigatus in a drosophila melanogaster infection model","volume":"63","author":"Wurster","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0105","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1086\/597615","article-title":"Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis","volume":"199","author":"Lamaris","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.mycmed.2020.101007_bib0110","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/cid\/ciz282","article-title":"Isavuconazole prophylaxis in patients with hematologic malignancies and hematopoietic-cell transplant recipients","volume":"70","author":"Fontana","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mycmed.2020.101007_bib0115","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1093\/mmy\/myy052","article-title":"Broad spectrum triazoles for invasive mould infections in adults: which drug and when?","volume":"57","author":"Jenks","year":"2019","journal-title":"Med Mycol"},{"key":"10.1016\/j.mycmed.2020.101007_bib0120","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3390\/jof5030059","article-title":"Mucormycosis of the central nervous system","volume":"5","author":"Chikley","year":"2019","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.mycmed.2020.101007_bib0125","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01292-17","article-title":"Tissue distribution and elimination of isavuconazole following single and repeat oral-dose administration of isavuconazonium sulfate to rats","volume":"61","author":"Schmitt-Hoffmann","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0130","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jac\/dkz050","article-title":"Isavuconazole brain penetration in cerebral aspergillosis","volume":"74","author":"Lamoth","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0135","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/mmy\/myz103","article-title":"Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system","volume":"58","author":"Schwartz","year":"2019","journal-title":"Med Mycol"},{"key":"10.1016\/j.mycmed.2020.101007_bib0140","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1093\/mmy\/myx101","article-title":"Challenges in the diagnosis and treatment of mucormycosis","volume":"56","author":"Skiada","year":"2018","journal-title":"Med Mycol"},{"key":"10.1016\/j.mycmed.2020.101007_bib0145","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1093\/jac\/dkx263","article-title":"Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease","volume":"72","author":"Cornely","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0150","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/jac\/dkv380","article-title":"Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease","volume":"71","author":"Cornely","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0155","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1128\/AAC.02686-13","article-title":"Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease","volume":"58","author":"Maertens","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0160","doi-asserted-by":"crossref","first-page":"5758","DOI":"10.1128\/AAC.03050-14","article-title":"Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia","volume":"58","author":"Duarte","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0165","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1093\/jac\/dkz344","article-title":"Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn)","volume":"74","author":"Salmanton-Garc\u00eda","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0170","doi-asserted-by":"crossref","first-page":"S328","DOI":"10.1093\/mmy\/myz012","article-title":"Antifungal drugs: what brings the future?","volume":"57","author":"Van Daele","year":"2019","journal-title":"Med Mycol"},{"key":"10.1016\/j.mycmed.2020.101007_bib0175","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1128\/AAC.00234-15","article-title":"Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates","volume":"59","author":"Lamoth","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0180","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00487-18","article-title":"EUCAST determination of olorofim (F901318) susceptibility of mold species, method validation, and MICs","volume":"62","author":"J\u00f8rgensen","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0185","doi-asserted-by":"crossref","first-page":"7815","DOI":"10.1128\/AAC.01437-15","article-title":"VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection","volume":"59","author":"Gebremariam","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0190","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00390-17","article-title":"Prophylactic treatment with VT-1161 protects immunosuppressed mice from Rhizopus arrhizus var. arrhizus Infection","volume":"61","author":"Gebremariam","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0195","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/jac\/33.2.369","article-title":"Treatment of murine pulmonary mucormycosis with SCH 42427, a broad-spectrum triazole antifungal drug","volume":"33","author":"Goldani","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0200","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1128\/AAC.00291-11","article-title":"In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds","volume":"55","author":"Miyazaki","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0205","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/jac\/dkz022","article-title":"In vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies","volume":"74","author":"Rivero-Menendez","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0210","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00178-20","article-title":"Fosmanogepix (APX001) is effective in the treatment of pulmonary murine mucormycosis due to Rhizopus arrhizus","volume":"64","author":"Gebremariam","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0215","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01941-17","article-title":"In vitro and in vivo efficacy of a novel and long-acting fungicidal azole, PC1244, on Aspergillus fumigatus infection","volume":"62","author":"Colley","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0220","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1128\/AAC.00956-09","article-title":"Antifungal activity of colistin against mucorales species in vitro and in a murine model of Rhizopus oryzae pulmonary infection","volume":"54","author":"Ben-Ami","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0225","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01244-19","article-title":"Therapeutic challenges of non-Aspergillus invasive mold infections in immunosuppressed patients","volume":"63","author":"Lamoth","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0230","first-page":"1734","article-title":"Posaconazole-loaded leukocytes as a novel treatment strategy targeting invasive pulmonary Aspergillosis","volume":"215","author":"Baistrocchi","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.mycmed.2020.101007_bib0235","doi-asserted-by":"crossref","first-page":"10660","DOI":"10.1073\/pnas.1312789111","article-title":"Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection","volume":"111","author":"Kumaresan","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.mycmed.2020.101007_bib0240","doi-asserted-by":"crossref","first-page":"eaaw1327","DOI":"10.1126\/sciadv.aaw1327","article-title":"Anti-CotH3 antibodies protect mice from mucormycosis by prevention of invasion and augmenting opsonophagocytosis","volume":"5","author":"Gebremariam","year":"2019","journal-title":"Sci Adv"},{"key":"10.1016\/j.mycmed.2020.101007_bib0245","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1172\/JCI42164","article-title":"The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice","volume":"120","author":"Liu","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.mycmed.2020.101007_bib0250","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jinf.2018.06.016","article-title":"Reactivation of dormant\/latent fungal infection","volume":"77","author":"Brunet","year":"2018","journal-title":"J Infect"},{"key":"10.1016\/j.mycmed.2020.101007_bib0255","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02010-17","article-title":"Robust phagocyte recruitment controls the opportunistic fungal pathogen Mucor circinelloides in innate granulomas in vivo","volume":"9","author":"Inglesfield","year":"2018","journal-title":"MBio"},{"key":"10.1016\/j.mycmed.2020.101007_bib0260","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1084\/jem.108.1.171","article-title":"Activation of quiescent mucormycotic granulomata in rabbits by induction of acute alloxan diabetes","volume":"108","author":"Sheldon","year":"1958","journal-title":"J Exp Med"},{"key":"10.1016\/j.mycmed.2020.101007_bib0265","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02544-18","article-title":"Lichtheimia corymbifera colonization leading to pulmonary infection can be prevented with liposomal amphotericin B in a new murine model","volume":"63","author":"Brunet","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0270","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ijantimicag.2019.01.002","article-title":"Contemporary management and clinical outcomes of mucormycosis: a systematic review and meta-analysis of case reports","volume":"53","author":"Jeong","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.mycmed.2020.101007_bib0275","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/myc.12909","article-title":"Antifungal combinations in Mucorales: a microbiological perspective","volume":"62","author":"Schwarz","year":"2019","journal-title":"Mycoses"},{"key":"10.1016\/j.mycmed.2020.101007_bib0280","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1128\/AAC.02612-12","article-title":"Drug combinations against Mucor irregularis in vitro","volume":"57","author":"Zhang","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0285","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1128\/AAC.00595-07","article-title":"Synergistic effect of posaconazole and caspofungin against clinical zygomycetes","volume":"51","author":"Guembe","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0290","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/jac\/dkw433","article-title":"Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis","volume":"72","author":"Gebremariam","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0295","doi-asserted-by":"crossref","first-page":"6767","DOI":"10.1128\/AAC.03569-14","article-title":"Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis","volume":"58","author":"Lewis","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0300","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1128\/AAC.01458-07","article-title":"Combination echinocandin-polyene treatment of murine mucormycosis","volume":"52","author":"Ibrahim","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0305","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1128\/AAC.49.2.830-832.2005","article-title":"Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice","volume":"49","author":"Spellberg","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0310","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/myc.12222","volume":"57","author":"Abidi","year":"2014","journal-title":"Mycoses"},{"key":"10.1016\/j.mycmed.2020.101007_bib0315","doi-asserted-by":"crossref","first-page":"811e1","DOI":"10.1016\/j.cmi.2016.03.029","article-title":"Initial use of combination treatment does not impact survival of 106\u00a0patients with haematologic malignancies and mucormycosis: a propensity score analysis","volume":"22","author":"Kyvernitakis","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.mycmed.2020.101007_bib0320","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1086\/500212","article-title":"Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91\u00a0cases","volume":"42","author":"van Burik J-AH","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mycmed.2020.101007_bib0325","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1093\/cid\/cir880","article-title":"A global analysis of mucormycosis in France: the RetroZygo Study (2005\u20132007)","volume":"54","author":"Lanternier","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mycmed.2020.101007_bib0330","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1086\/589857","article-title":"Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis","volume":"47","author":"Reed","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mycmed.2020.101007_bib0335","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1172\/JCI32338","article-title":"The iron chelator deferasirox protects mice from mucormycosis through iron starvation","volume":"117","author":"Ibrahim","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.mycmed.2020.101007_bib0340","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1128\/AAC.01577-10","article-title":"Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins","volume":"55","author":"Ibrahim","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0345","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1128\/AAC.00184-09","article-title":"In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes","volume":"53","author":"Dannaoui","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0350","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/infdis\/jis767","article-title":"Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosis","volume":"207","author":"Lewis","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.mycmed.2020.101007_bib0355","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1093\/jac\/dkz102","article-title":"In vitro interactions between isavuconazole and tacrolimus, cyclosporin A or sirolimus against Mucorales","volume":"74","author":"Schwarz","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0360","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1128\/JCM.00618-09","article-title":"Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens","volume":"47","author":"Pfaller","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.mycmed.2020.101007_bib0365","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1128\/AAC.50.1.96-103.2006","article-title":"Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole","volume":"50","author":"Chamilos","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0370","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1128\/AAC.44.7.2004-2006.2000","article-title":"Combination antifungal therapy in treatment of murine pulmonary mucormycosis: roles of quinolones and azoles","volume":"44","author":"Sugar","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0375","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1093\/jac\/dkt282","article-title":"In vitro activity of miltefosine as a single agent and in combination with voriconazole or posaconazole against uncommon filamentous fungal pathogens","volume":"68","author":"Biswas","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0380","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1128\/AAC.46.8.2708-2711.2002","article-title":"In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents","volume":"46","author":"Dannaoui","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0385","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1128\/AAC.31.11.1775","article-title":"Synergistic action of amphotericin B and rifampin against Rhizopus species","volume":"31","author":"Christenson","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0390","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1093\/cid\/cir885","article-title":"Combination therapy for mucormycosis: why, what, and how?","volume":"54","author":"Spellberg","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mycmed.2020.101007_bib0395","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s15010-017-0991-6","article-title":"Pulmonary mucormycosis: clinical features and outcomes","volume":"45","author":"Lin","year":"2017","journal-title":"Infection"},{"key":"10.1016\/j.mycmed.2020.101007_bib0400","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/0003-4975(94)90243-7","article-title":"Pulmonary mucormycosis: results of medical and surgical therapy","volume":"57","author":"Tedder","year":"1994","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.mycmed.2020.101007_bib0405","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11908-012-0272-6","article-title":"Rhino-orbital-cerebral mucormycosis","volume":"14","author":"Gamaletsou","year":"2012","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.mycmed.2020.101007_bib0410","doi-asserted-by":"crossref","first-page":"O336","DOI":"10.1111\/1469-0691.12408","article-title":"Local control of rhino-orbito-cerebral mucormycosis dramatically impacts survival","volume":"20","author":"Vironneau","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.mycmed.2020.101007_bib0415","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/myc.12897","article-title":"Mucormycosis\u2014A clinicoepidemiological review of cases over 10\u00a0years","volume":"62","author":"Manesh","year":"2019","journal-title":"Mycoses"},{"key":"10.1016\/j.mycmed.2020.101007_bib0420","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1086\/428503","article-title":"Interferon-gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes","volume":"191","author":"Gil-Lamaignere","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.mycmed.2020.101007_bib0425","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1086\/513961","article-title":"Granulocyte colony-stimulating factor administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens","volume":"175","author":"Liles","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.mycmed.2020.101007_bib0430","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1111\/j.1439-0507.2010.01958.x","article-title":"Antifungal activity of posaconazole and granulocyte colony-stimulating factor in the treatment of disseminated zygomycosis (mucormycosis) in a neutropaenic murine model","volume":"54","author":"Saoulidis","year":"2011","journal-title":"Mycoses"},{"key":"10.1016\/j.mycmed.2020.101007_bib0435","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1128\/AAC.00456-09","article-title":"Efficacy of liposomal amphotericin B combined with gamma interferon or granulocyte-macrophage colony-stimulating factor for treatment of systemic zygomycosis in mice","volume":"53","author":"Rodr\u00edguez","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0440","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.3109\/10428190109097768","article-title":"Cure of pulmonary Rhizomucor pusillus infection in a patient with hairy-cell leukemia: role of liposomal amphotericin B and GM-CSF","volume":"42","author":"Ma","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.mycmed.2020.101007_bib0445","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/BF01691218","article-title":"Role of granulocyte colony-stimulating factor in the treatment of mucormycosis","volume":"15","author":"Sahin","year":"1996","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.mycmed.2020.101007_bib0450","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1086\/320767","article-title":"Resolution of rhinocerebral zygomycosis associated with adjuvant administration of granulocyte-macrophage colony-stimulating factor","volume":"32","author":"Garcia-Diaz","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mycmed.2020.101007_bib0455","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/01.inf.0000134314.65398.bf","article-title":"Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children","volume":"23","author":"Abzug","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.mycmed.2020.101007_bib0460","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1469-0691.2009.02976.x","article-title":"The role of iron and iron chelators in zygomycosis","volume":"15","author":"Symeonidis","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.mycmed.2020.101007_bib0465","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/jac\/dkl350","article-title":"Deferiprone iron chelation as a novel therapy for experimental mucormycosis","volume":"58","author":"Ibrahim","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0475","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00266-19","article-title":"In vitro activity of combinations of zinc chelators with amphotericin B and posaconazole against six mucorales species","volume":"63","author":"Leonardelli","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0480","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1469-0691.2009.02986.x","article-title":"Hyperbaric oxygen therapy and other adjunctive treatments for zygomycosis","volume":"15","author":"Tragiannidis","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.mycmed.2020.101007_bib0485","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1128\/AAC.45.12.3601-3602.2001","article-title":"Hyperbaric oxygen as an adjunct in zygomycosis: randomized controlled trial in a murine model","volume":"45","author":"Barratt","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0490","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1469-0691.2005.01170.x","article-title":"Hyperbaric oxygen as an adjunctive treatment for zygomycosis","volume":"11","author":"John","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.mycmed.2020.101007_bib0495","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1128\/AAC.00285-09","article-title":"Efficacy of combination antifungal therapy with intraperitoneally administered micafungin and aerosolized liposomal amphotericin B against murine invasive pulmonary aspergillosis","volume":"53","author":"Takazono","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0500","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jiac.2013.09.002","article-title":"Efficacy of aerosolized liposomal amphotericin B against murine invasive pulmonary mucormycosis","volume":"20","author":"Mihara","year":"2014","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0505","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/LBR.0b013e3181aa2583","article-title":"Endobronchial instillations of amphotericin B: complementary treatment for pulmonary mucormycosis","volume":"16","author":"Alfageme","year":"2009","journal-title":"J Bronchology Interv Pulmonol"},{"key":"10.1016\/j.mycmed.2020.101007_bib0510","first-page":"309","article-title":"[Pulmonary mucormycosis: benefit of aerosol amphotericin B?]","volume":"18","author":"Furco","year":"2001","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.mycmed.2020.101007_bib0515","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.healun.2007.05.010","article-title":"Mucormycosis of the bronchial anastomosis: a case of successful medical treatment and historic review","volume":"26","author":"McGuire","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.mycmed.2020.101007_bib0520","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/sj.bmt.1704552","article-title":"Efficacy and feasibility of aerosolized amphotericin B lipid complex therapy in caspofungin breakthrough pulmonary zygomycosis","volume":"34","author":"Safdar","year":"2004","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.mycmed.2020.101007_bib0525","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/phar.1309","article-title":"Aerosolized amphotericin B lipid complex as adjunctive treatment for fungal lung infection in patients with cancer-related immunosuppression and recipients of hematopoietic stem cell transplantation","volume":"33","author":"Safdar","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.mycmed.2020.101007_bib0530","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1097\/MPH.0000000000000166","article-title":"Topical amphotericin B in combination with standard therapy for severe necrotizing skin and soft-tissue mucormycosis in an infant with bilineal leukemia: case report and review","volume":"36","author":"Di Pentima","year":"2014","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.mycmed.2020.101007_bib0535","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1001\/archderm.142.12.1657","article-title":"Zygomycosis of the penis due to Rhizopus oryzae successfully treated with surgical debridement and a combination of high-dose liposomal and topical amphotericin B","volume":"142","author":"Cohen-Ludmann","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.mycmed.2020.101007_bib0540","doi-asserted-by":"crossref","first-page":"e1927","DOI":"10.1097\/GOX.0000000000001927","article-title":"Orbitomaxillofacial mucormycosis requiring complex multifactorial management","volume":"6","author":"Steve","year":"2018","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"10.1016\/j.mycmed.2020.101007_bib0545","article-title":"Mucormycosis in burn patients","volume":"5","author":"Devauchelle","year":"2019","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.mycmed.2020.101007_bib0550","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11046-018-0281-6","article-title":"Widespread Lichtheimia infection in a patient with extensive burns: opportunities for novel antifungal agents","volume":"184","author":"Thielen","year":"2019","journal-title":"Mycopathologia"},{"key":"10.1016\/j.mycmed.2020.101007_bib0555","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1128\/JCM.00410-15","article-title":"Combat-Related Pythium aphanidermatum invasive wound infection: case report and discussion of utility of molecular diagnostics","volume":"53","author":"Farmer","year":"2015","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.mycmed.2020.101007_bib0560","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/BCR.0b013e3181a28d2f","article-title":"Mucormycosis of the face","volume":"30","author":"Piazza","year":"2009","journal-title":"J Burn Care Res"},{"key":"10.1016\/j.mycmed.2020.101007_bib0565","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamadermatol.2014.2463","article-title":"Black plaques and white nodules in a burn patient. Fusarium and Mucormycosis","volume":"150","author":"Atty","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.mycmed.2020.101007_bib0570","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0305-4179(97)00099-5","article-title":"Successful cure of an extensive burn injury complicated with mucor wound sepsis","volume":"24","author":"Tang","year":"1998","journal-title":"Burns"},{"key":"10.1016\/j.mycmed.2020.101007_bib0575","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/BCR.0b013e318166da78","article-title":"Absidia corymbifera fungal infection in burns: a case report and review of the literature","volume":"29","author":"Constantinides","year":"2008","journal-title":"J Burn Care Res"},{"key":"10.1016\/j.mycmed.2020.101007_bib0580","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.3109\/10717544.2016.1153747","article-title":"Formulation and optimization of nanoemulsion using antifungal lipid and surfactant for accentuated topical delivery of Amphotericin B","volume":"23","author":"Hussain","year":"2016","journal-title":"Drug Deliv"},{"key":"10.1016\/j.mycmed.2020.101007_bib0585","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/j.nano.2017.06.021","article-title":"releasing topical nanoemulsion for the treatment of candidiasis and aspergillosis","volume":"13","author":"Sosa","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.mycmed.2020.101007_bib0590","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00729-19","article-title":"Nanoemulsion as an effective treatment against human-pathogenic fungi","volume":"4","author":"Garcia","year":"2019","journal-title":"MSphere"},{"key":"10.1016\/j.mycmed.2020.101007_bib0595","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.oftal.2014.02.020","article-title":"Keratitis caused by Absidia corymbifera in an immunocompetent male with no corneal injuries","volume":"90","author":"Mesa Varona","year":"2015","journal-title":"Arch Soc Esp Oftalmol"},{"key":"10.1016\/j.mycmed.2020.101007_bib0600","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.mmcr.2017.05.004","article-title":"Combination liposomal amphotericin B, posaconazole and oral amphotericin B for treatment of gastrointestinal Mucorales in an immunocompromised patient","volume":"17","author":"Anderson","year":"2017","journal-title":"Med Mycol Case Rep"},{"key":"10.1016\/j.mycmed.2020.101007_bib0605","article-title":"Successful treatment of Saksenaea sp. osteomyelitis by conservative surgery and intradiaphyseal incorporation of amphotericin B cement beads","volume":"63","author":"Parize","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2020.101007_bib0610","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.jocn.2014.01.008","article-title":"Use of external ventriculostomy and intrathecal anti-fungal treatment in cerebral mucormycotic abscess","volume":"21","author":"Grannan","year":"2014","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.mycmed.2020.101007_bib0615","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11046-018-0273-6","article-title":"Successful treatment of eczema-like mucormycosis in a child by combination of intravenous drip and percutaneous injection amphotericin B","volume":"184","author":"Fu","year":"2019","journal-title":"Mycopathologia"}],"container-title":["Journal de Mycologie M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1156523320301190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1156523320301190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:20:10Z","timestamp":1761110410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1156523320301190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":122,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1156523320301190"],"URL":"https:\/\/doi.org\/10.1016\/j.mycmed.2020.101007","relation":{},"ISSN":["1156-5233"],"issn-type":[{"value":"1156-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mucormycosis treatment: Recommendations, latest advances, and perspectives","name":"articletitle","label":"Article Title"},{"value":"Journal de Mycologie M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mycmed.2020.101007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101007"}}